Drug Trial Radar · NCT04404569
Continued Treatment for Participants Enrolled in Studies of BXQ-350
Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Jun 8, 2020
Primary completion
Sep 23, 2024
Study completion Sep 23, 2024
Sponsor
- Lead sponsor
- Bexion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CTI Clinical Trial and Consulting Services
- First posted
- May 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.
Conditions
- Neoplasms
Interventions
BXQ-350Drug
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with clinical benefitTime frame: Day 1 up to approximately 5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Kentucky Markey Cancer Center
Lexington, Kentucky
University of Cincinnati Barrett Center
Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.